LOG IN
SIGN UP
MARKET
ICPT
ICPT
Intercept Pharmaceuticals Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
18.57
+1.17
+6.72%
After Hours: 18.03 -0.54 -2.91% 17:27 05/27 EDT
OPEN
17.40
PREV CLOSE
17.40
HIGH
18.65
LOW
17.27
VOLUME
707.06K
TURNOVER
0
52 WEEK HIGH
22.36
52 WEEK LOW
11.60
MARKET CAP
551.77M
P/E (TTM)
-8.2201
1D
5D
1M
3M
1Y
5Y
Biotech Stock Roundup: REGN, VRTX Earnings Update, BHVN Up on Regulatory News
Earnings and regulatory updates from Regeneron (REGN) and Vertex (VRTX) are a few key highlights from the biotech sector during the past week.
Zacks · 05/12 13:11
First Patient Dosed in Phase 2 Study of Intercept's OCA and Bezafibrate Combination for Primary Biliary Cholangitis
Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) dosed first patient in a Phase 2 study evaluating a fixed-dose combination of obeticholic acid (OCA) and bezafibrate (BZF) for the treatment of patients with primary biliary cholangitis (PBC).
Benzinga · 05/11 14:10
Intercept begins dosing in phase 2 study to treat primary biliary cholangitis
Intercept Pharma (NASDAQ:ICPT) said on Wednesday the first patient had been dosed in a Phase 2 study evaluating a fixed-dose combination of its drug, obeticholic acid with bezafibrate for the treatment of
Seekingalpha · 05/11 13:18
Intercept Announces First Patient Dosed In Phase 2 Study Of OCA And Bezafibrate For The Treatment Of Primary Biliary Cholangitis
Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced the
Benzinga · 05/11 12:01
Intercept Pharmaceuticals Doses First Patient in Phase 2 Study to Treat Primary Biliary Cholangitis
MT Newswires · 05/11 09:59
Party Time: Brokers Just Made Major Increases To Their Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT) Earnings Forecasts
Celebrations may be in order for Intercept Pharmaceuticals, Inc. ( NASDAQ:ICPT ) shareholders, with the analysts...
Simply Wall St. · 05/10 10:16
--B. Riley Raises Intercept Pharmaceuticals' Price Target to $32 from $30, Keeps Buy Rating
MT Newswires · 05/10 09:46
Analysts Expect Clarity Imminent On Intercept's NASH Story
Benzinga · 05/09 18:15
No Data
Learn about the latest financial forecast of ICPT. Analyze the recent business situations of Intercept Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 16 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
6.25%Strong Buy
25.00%Buy
56.25%Hold
12.50%Under-perform
0.00%Sell
Analyst Price Target
The average ICPT stock price target is 27.67 with a high estimate of 82.00 and a low estimate of 10.00.
Current 18.57
EPS
Actual
Estimate
-0.98-0.74-0.49-0.25
Institutional Holdings
Institutions: 286
Institutional Holdings: 26.03M
% Owned: 87.60%
Shares Outstanding: 29.71M
TypeInstitutionsShares
Increased
45
2.75M
New
20
746.44K
Decreased
48
2.98M
Sold Out
21
761.70K
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+3.72%
Pharmaceuticals & Medical Research
+1.28%
Key Executives
Non-Executive Chairman/Independent Director
Paolo Fundaro
President/Chief Executive Officer/Director
Jerome Durso
Chief Financial Officer
Andrew Saik
Corporate Executive
M. Michelle Berrey
Chief Human Resource Officer
David Ford
Senior Vice President
Bryan Ball
Senior Vice President
Gail Cawkwell
Chief Accounting Officer
Rocco Venezia
General Counsel
Jared Freedberg
Other
Linda Richardson
Lead Director/Independent Director
Gino Santini
Director
Mark Pruzanski
Independent Director
Srinivas Akkaraju
Independent Director
Luca Benatti
Independent Director
Daniel Bradbury
Independent Director
Keith Gottesdiener
Independent Director
Nancy Miller-Rich
Independent Director
Dagmar Rosa-bjorkeson
Independent Director
Glenn Sblendorio
No Data
No Data
About ICPT
Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat progressive non-viral liver diseases with unmet medical need utilizing its bile acid chemistry. The Company’s product candidates include Ocaliva (obeticholic or OCA) for liver fibrosis due to nonalcoholic steatohepatitis (NASH), OCA and Bezafibrate, and Other Product Candidates. The Company’s marketed product, Ocaliva, is a farnesoid X receptor (FXR) agonist for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. In addition to commercializing OCA for PBC, it is also developing OCA for additional indications, including NASH. The Company is also developing product candidates in various stages of clinical and preclinical development.
Webull offers kinds of Intercept Pharmaceuticals Inc stock information, including NASDAQ:ICPT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICPT stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading ICPT stock methods without spending real money on the virtual paper trading platform.